Clinical Trial Update: A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients [Phase 2]

View source ↗

Summary

Phase 2a trial evaluating safety, daily symptoms, pharmacokinetics, and biomarkers of YPL-001 in COPD patients has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• YPL-001

Snippet

Sponsor: Yungjin Pharm. Co., Ltd. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-06-25